gout: A condition characterized by painful swelling of the joints, which is caused by deposition of urate crystals.
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters: 2 out of 7 registries used, show all original rules. |
106 |
4. Check minimum number of eventsNone |
106 |
5. Include endpointsNone |
106 |
6. Filter based on genotype QC (FinnGen only) |
106 |
Control definitions (FinnGen only)
- Control exclude
- GOUT
Extra metadata
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- M10
- Name in latin
- Alia arthritis urica secundaria
Other secondary gout
based on the number of shared cases.
Similar with more cases:
Similar with less cases:
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 964 | 358 | 599 |
| Only index persons | 824 | 302 | 522 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.01 | 0.01 | 0.02 |
| Only index persons | 0.02 | 0.01 | 0.02 |
| Median age at first event (years) | |||
| Whole population | 71.27 | 76.27 | 68.30 |
| Only index persons | 70.71 | 75.58 | 67.90 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 106 | 31 | 75 |
| Unadjusted period prevalence (%) | 0.03 | 0.01 | 0.03 |
| Median age at first event (years) | 66.91 | 65.07 | 67.68 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 96
- Matched controls
- 961
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
M10.4
ICD-10 Finland
Other secondary gout
+∞
138.3
96
*
M04AA01
ATC
allopurinol; systemic
19.6
34.7
61
78
M10.9
ICD-10 Finland
Gout, unspecified
29.0
27.8
38
21
M10.0
ICD-10 Finland
Idiopathic gout
26.1
17.5
24
12
C03CA01
ATC
furosemide; systemic
6.6
16.6
67
249
I50.9
ICD-10 Finland
Heart failure, unspecified
7.4
16.0
45
102
N18.9
ICD-10 Finland
Chronic kidney disease, unspecified
10.4
15.8
33
46
212
Kela drug reimbursment
Gout
+∞
13.9
13
*
N18.8
ICD-10 Finland
Other chronic renal failure
21.8
12.6
18
10
M10
ICD-10 Finland
Gout
13.8
12.3
21
19
I48
ICD-10 Finland
Atrial fibrillation and flutter
5.2
12.3
49
161
B01AA03
ATC
warfarin; systemic
5.1
12.1
48
156
123
Kela drug reimbursment
Chronic disorders of vitamin D metabolism
22.6
12.1
17
9
I50.0
ICD-10 Finland
Congestive heart failure
7.3
11.8
30
56
A11CC03
ATC
alfacalcidol; systemic
21.9
10.7
15
8
205
Kela drug reimbursment
Chronic hypertension
4.4
10.5
51
196
138
Kela drug reimbursment
Severe anaemia associated with chronic renal failure
16.1
9.0
14
10
I50.1
ICD-10 Finland
Left ventricular failure
7.9
8.8
20
31
C03DA01
ATC
spironolactone; oral
5.0
8.7
30
80
N02AE01
ATC
buprenorphine; parenteral, sublingual, transdermal
5.1
8.6
29
75
H02AB06
ATC
prednisolone; systemic
3.7
8.4
61
309
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
3.7
8.1
47
199
C07AB07
ATC
bisoprolol; oral
3.6
8.0
68
386
R06.0
ICD-10 Finland
Dyspnoea
3.9
8.0
40
150
N02AA05
ATC
oxycodone; systemic
4.6
7.9
30
87
C09AA02
ATC
enalapril; systemic
3.9
7.9
38
138
WX700
NOMESCO Finland
Respiratory and circulatory monitoring
4.4
7.8
30
89
A46
ICD-10 Finland
Erysipelas
4.2
7.7
32
102
J01MA12
ATC
levofloxacin; systemic
3.9
7.4
34
118
M01AB01
ATC
indometacin; systemic, rectal
6.3
7.3
19
36
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
3.9
7.2
33
114
FM1EE
NOMESCO Finland
Extensive structural and functional ultrasound examination of heart
3.6
7.0
37
143
N03AX12
ATC
gabapentin; oral
4.3
6.9
27
80
A12AA04
ATC
calcium carbonate; oral
18.4
6.9
10
6
FM1DE
NOMESCO Finland
Doppler ultrasound examination of heart
5.1
6.9
22
53
A10BH05
ATC
linagliptin; oral
7.2
6.8
16
26
TPH04
NOMESCO Finland
Cathetrisation of vein
3.7
6.8
33
119
WX002
NOMESCO Finland
Sedation and analgesia
3.7
6.8
33
119
290
Kela drug reimbursment
Apixaban, dabigatran, edoxaban and rivaroxaban for the treatment of atrial fibrillation
4.0
6.6
28
90
JN1AE
NOMESCO Finland
Ultrasound examination of upper part of abdomen
5.5
6.6
19
41
B03XA02
ATC
darbepoetin alfa; parenteral
15.7
6.6
10
7
I15.1
ICD-10 Finland
Hypertension secondary to other renal disorders
74.6
6.5
7
*
351
Kela drug reimbursment
Apixaban, dabigatran, edoxaban and rivaroxaban for the treatment of atrial fibrillation
4.3
6.5
25
73
R10.1
ICD-10 Finland
Pain localized to upper abdomen
4.3
6.5
25
73
N19
ICD-10 Finland
Unspecified kidney failure
7.2
6.5
15
24
XFP20
NOMESCO Finland
Check up of cardiac pacemaker
6.0
6.4
17
33
137
Kela drug reimbursment
Uraemia requiring dialysis
+∞
6.3
6
*
B05DA
ATC
Isotonic solutions
+∞
6.3
6
*
M10.3
ICD-10 Finland
Gout due to impairment of renal function
+∞
6.3
6
*
E11.2
ICD-10 Finland
Type 2 diabetes mellitus, with renal complications
7.6
6.3
14
21
J01DB01
ATC
cefalexin; oral
4.0
6.1
84
613
E11.8
ICD-10 Finland
Type 2 diabetes mellitus, with unspecified complications
4.3
6.1
23
66
GD1AA
NOMESCO Finland
Thorax X-ray examination
2.9
6.1
59
339
A49.9
ICD-10 Finland
Bacterial infection, unspecified
4.0
6.0
25
78
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
69
210
7.55
24.15
6.3
2.8
453.9
8714.5
umol/l
1.25
63
173
48
123
6.30
19.45
4.9
2.2
22.0
23.3
%
0.23
42
112
48
130
5.92
18.14
4.8
2.1
2.1
2.3
g/l
1.41
48
118
49
137
5.79
17.82
4.8
2.1
11.7
13.6
umol/l
0.97
49
126
48
139
5.48
16.60
3.5
2.9
0.8
0.8
mmol/l
0.19
43
129
17
18
11.06
14.73
1.6
1.5
—
—
—
0
0
45
146
4.62
13.09
2.5
2.0
—
—
—
0
0
78
402
4.56
11.62
15.9
6.4
1.2
1.2
mmol/l
0.22
71
340
31
84
4.80
11.13
8.2
4.6
2.3
2.0
mmol/l
0.11
26
65
14
18
8.81
10.40
1.4
1.3
—
—
—
0
0
72
372
3.92
10.19
12.5
5.9
1.2
1.2
mmol/l
0.16
65
336
37
125
4.01
9.84
26.3
23.6
1.6
1.2
inr
—
8
12
24
58
5.06
9.79
2.1
1.4
—
—
—
0
0
63
325
3.31
8.40
5.8
3.4
—
—
—
0
0
46
197
3.36
8.36
3.3
2.3
—
—
—
0
0
79
470
3.67
8.27
12.8
9.7
4.8
4.5
e9/l
0.42
70
408
23
62
4.46
8.15
2.6
1.8
—
—
—
0
0
14
25
6.30
7.77
1.6
1.1
—
—
—
0
0
29
99
3.66
7.41
2.6
1.9
—
—
—
0
0
10
13
8.39
7.24
2.4
1.4
—
—
—
0
0
63
345
3.04
7.24
2.7
1.9
88.0
89.5
pmol/l
0.07
42
185
11
17
7.10
6.92
1.3
1.4
—
—
—
0
0
11
17
7.10
6.92
1.3
1.4
—
—
—
0
0
29
104
3.46
6.84
6.2
6.4
11.6
11.6
kpa
0.02
29
99
29
104
3.46
6.84
6.1
6.4
4.9
5.0
kpa
0.21
29
99
50
249
2.91
6.72
5.1
2.8
37.6
36.0
u/l
0.11
50
232
15
33
5.13
6.69
2.2
1.9
—
—
—
0
0
12
22
6.02
6.45
2.5
1.2
—
—
—
0
0
15
36
4.69
6.05
2.7
2.3
—
—
—
0
0
15
36
4.69
6.05
4.1
1.5
—
—
—
0
0
27
100
3.28
6.00
2.7
2.0
—
—
—
0
0
48
250
2.68
5.73
7.0
4.0
25.2
10.9
mg/mmol
0.95
39
164
62
378
2.54
5.21
7.9
3.9
—
—
—
0
0
10
19
5.71
5.15
1.5
1.2
—
—
—
0
0
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
13
34
4.22
4.69
3.5
2.1
0.3
0.3
u/ml
—
7
17
11
25
4.79
4.68
5.2
1.5
0.0
0.0
g/l
0.00
11
25
17
57
3.36
4.35
4.4
6.4
23.4
24.6
mmol/l
0.66
17
57
16
53
3.38
4.17
1.9
3.2
0.7
0.1
e6/l
0.88
16
53
10
24
4.50
3.98
1.1
1.0
—
—
—
0
0
20
82
2.77
3.64
3.7
3.8
—
—
—
0
0
28
137
2.42
3.59
4.4
1.7
32.3
29.7
s
0.70
28
131
11
31
3.84
3.59
5.2
1.4
35.1
37.0
g/l
0.45
11
26
23
104
2.55
3.47
1.3
1.3
5.5
7.3
u/ml
—
5
39
30
155
2.30
3.39
4.5
2.8
1.5
0.9
e6/l
0.30
17
92
29
148
2.32
3.37
4.9
3.0
0.8
1.7
e6/l
0.62
16
86
15
56
2.96
3.21
5.2
8.8
23.6
24.4
mmol/l
0.37
15
51
17
69
2.74
3.15
1.6
2.0
1.9
1.8
%
0.15
17
58
24
119
2.31
2.95
1.5
1.2
22.4
39.8
iu/ml
—
6
36
9
23
4.17
2.85
1.7
1.3
—
—
—
0
0
5
6
8.66
2.78
1.8
1.3
—
—
—
0
0
61
442
1.90
2.62
3.7
2.5
—
—
—
0
0
14
58
2.63
2.49
1.5
1.5
—
—
—
0
0
15
66
2.48
2.37
2.0
1.9
0.2
0.2
g/l
0.11
15
59
15
68
2.40
2.23
8.3
4.1
43.3
60.4
ml/min/173m2
—
6
35
15
69
2.37
2.16
2.4
2.2
364.3
380.2
nmol/l
0.07
15
60
9
31
3.08
2.13
2.6
2.3
—
—
—
0
0
51
368
1.74
2.07
9.1
4.4
43.9
50.7
ng/l
0.20
40
272
84
702
1.95
2.05
4.6
4.3
2.0
2.0
mu/l
0.10
77
612
6
16
3.91
1.96
1.7
1.4
—
—
—
0
0
5
11
4.71
1.96
1.6
1.4
—
—
—
0
0
5
11
4.71
1.96
1.2
1.2
—
—
—
0
0
6
17
3.67
1.86
1.3
1.9
—
—
—
0
0
55
415
1.68
1.84
5.1
4.0
0.0
0.0
estimate
—
9
71
54
409
1.65
1.76
6.7
5.6
0.0
0.0
estimate
—
9
78
5
13
3.98
1.73
1.6
1.1
—
—
—
0
0
6
19
3.28
1.68
1.5
2.3
—
—
—
0
0
7
25
2.92
1.68
6.3
3.1
25.1
36.5
mg/l
—
7
20
7
25
2.92
1.68
6.1
3.1
52.5
45.9
mg/l
—
7
20
5
14
3.69
1.63
1.4
2.1
—
—
—
0
0
7
26
2.81
1.61
1.9
1.3
—
—
—
0
0
67
550
1.59
1.47
3.8
3.6
14.8
14.9
pmol/l
0.10
62
482
9
42
2.25
1.37
1.3
2.0
—
—
—
0
0
5
17
3.03
1.37
1.2
2.2
—
—
—
0
0
86
759
1.71
1.32
44.9
15.1
60.0
76.6
ml/min/173m2
5.98
81
624
6
24
2.59
1.32
1.7
1.9
—
—
—
0
0
6
25
2.48
1.26
1.7
1.8
—
—
—
0
0
51
410
1.47
1.13
5.2
4.0
0.0
0.0
estimate
—
7
80
27
362
0.66
1.05
3.5
4.6
24.5
20.9
%
—
8
188
5
22
2.33
1.04
1.2
1.2
—
—
—
0
0
5
22
2.33
1.04
1.2
1.2
—
—
—
0
0
6
34
1.81
0.77
1.2
1.3
—
—
—
0
0
84
774
1.41
0.69
6.5
4.8
6.4
6.1
mmol/l
0.87
78
689
90
840
1.47
0.68
60.3
18.6
138.5
83.8
umol/l
5.74
90
840
5
28
1.82
0.67
1.2
3.4
—
—
—
0
0
8
52
1.58
0.61
1.4
2.0
—
—
—
0
0
40
461
0.79
0.52
4.0
5.3
1.6
3.2
ug/l
1.10
35
402
80
751
1.27
0.43
5.2
4.2
1.6
1.3
mmol/l
1.82
80
671
28
317
0.84
0.28
6.3
4.4
—
—
—
0
0
25
221
1.17
0.23
4.6
4.3
0.0
0.0
estimate
—
7
73
0
11
0.00
0.21
0.0
1.0
—
—
—
0
0
0
11
0.00
0.21
0.0
1.6
—
—
—
0
0
0
10
0.00
0.21
0.0
1.0
—
—
—
0
0
0
12
0.00
0.21
0.0
1.7
—
3.1
—
0
7
0
12
0.00
0.21
0.0
1.0
—
—
—
0
0
0
13
0.00
0.21
0.0
1.2
—
—
—
0
0
7
88
0.78
0.15
1.9
1.3
—
—
—
0
0
6
57
1.06
0.08
1.3
1.5
—
—
—
0
0
0
5
0.00
0.00
0.0
1.4
—
—
—
0
0
9
99
0.90
0.00
7.8
8.4
—
—
—
0
0
19
190
1.00
0.00
1.9
1.6
1.6
1.4
mmol/l
0.56
19
150
0
8
0.00
0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
0.00
0.0
1.6
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint GOUT_SCND and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| GOUT_SCND | 2.432 [1.7, 3.49] | < 0.001 |
| Birth year | 0.994 [0.99, 1.0] | 0.198 |
During the follow-up period (1.1.1998 — 31.12.2019), 157 out of 306 females with GOUT_SCND died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| GOUT_SCND | 3.031 [2.18, 4.21] | < 0.001 |
| Birth year | 0.986 [0.98, 1.0] | 0.003 |
During the follow-up period (1.1.1998 — 31.12.2019), 239 out of 515 males with GOUT_SCND died.
Mortality risk
Mortality risk for people of age
years, who have GOUT_SCND.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.272% | 0.647% |
| 5 | 1.404% | 3.526% |
| 10 | 3.392% | 7.938% |
| 15 | 6.578% | 14.883% |
| 20 | 11.242% | 24.572% |
Relationships between endpoints
↥Index endpoint: GOUT_SCND – Other secondary gout
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data